Analyst consensus rating
Dogwood Therapeutics Analyst Rating: Strong Buy
Direct answer
Dogwood Therapeutics's consensus rating is Strong Buy.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $14.00.
Forecast evidence checked September 7, 2026.
Get free Dogwood Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.29
- Average price target
- $14.00
- High price target
- $15.00
- Low price target
- $12.00
- Low target gap
- +424%
- Target upside
- +511.4%
- High target gap
- +555%
- Target range width
- 131%
- Consensus rating
- Strong Buy
- Analysts
- 3
- Evidence date
- September 7, 2026
- Valid through
- September 14, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Dogwood Therapeutics?
Dogwood Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $14.00.
How far are Dogwood Therapeutics's low and high targets from the recorded price?
The low target implies +424%, while the high target implies +555%.
How many analysts are included in Dogwood Therapeutics's consensus?
The verified consensus includes 3 analysts.
How is Dogwood Therapeutics's target upside or downside calculated?
The average target of $14.00 is divided by the recorded price of $2.29, then one is subtracted to produce +511.4%. This does not guarantee a future return.
When was Dogwood Therapeutics's analyst forecast verified?
The data was verified on 2026-09-07. The dataset is valid through 2026-09-14.